Positron Emission Tomography/Magnetic Resonance Imaging Practices in Oncological Imaging
Journal Title: Nükleer Tıp Seminerleri - Year 2017, Vol 3, Issue 1
Abstract
Biomedical imaging plays an increasingly important role in primary staging, biopsy guidance, prognostic assessment, selection of treatment protocol, monitoring of treatment response and assessment of recurrent disease in medical oncology. Positron emission tomography/magnetic resonance (PET/MR) imaging which is the third major hybrid imaging modality after combined PET/CT and single-photon emission computed tomography combines high resolution anatomical and functional data of MR imaging with the quantifiable functional and molecular information provided by PET with fluorodeoxyglucose (FDG) and other radiotracers. This imaging modality can provide potential clinical advantages and higher diagnostic accuracy in tumor staging, assessment of therapy response and detection of recurrent disease. Furthermore simultaneous PET/MR imaging has practical advantages including reduced scanning time, improved coregistration, MR imaging-based motion correction. PET/MR imaging also has an advantage over PET/CT in decreasing ionizing radiation exposure especially in patients who require multiple PET imagings. MR imaging has the advantage of high soft tissue contrast, so PET/MR imaging can be used instead of PET/CT in evaluation of primary and metastatic brain tumors, head and neck cancers, breast tumors, abdominopelvic tumors, assessment of intramedullary lesions in hematological malignencies or it can be used as regional imaging method which will be complementary to PET/CT. PET/CT is preferred especially in MR imaging-contraindicated situaitons and assessment of small pulmonary nodules. PET/CT is also more clinically available than PET/MR imaging. In the future, standardization of PET/MR imaging protocols, technical optimizations, technological advances, detection of optimal clinical indications of whole body and regional PET/MR imaging, usage of highly spesific non-FDG PET tracers and additional value of multiparametric MR imaging data will clarify clinical availability this new imaging method.
Authors and Affiliations
Uğuray Aydos, Ümit Özgür Akdemir, Lütfiye Özlem Atay
Keywords
Related Articles
- EP ID EP241221
- DOI 10.4274/nts.004
- Views 97
- Downloads 0
Treatment of Intrahepatic Cholangiocellular Carcinoma with Y-90 Labelled Microspheres
Intrahepatic cholangiocellular carcinoma (ICC) is a rapidly progressive malignancy of intrahepatic bile duct epithelium. ICC is the second most common primary malignant tumor of the liver which accounts for 10% to 20% of...
Breast Cancer Models
Breast cancer is the most common cancer in women. 11.5% of breast cancer patients are at distant stage and mortality is due to metastases rather than primary disease. Experimental breast cancer tumor models are validated...
TNM Staging of Lung Cancer
Staging lung cancer is based on whether the cancer is local or has spread from the lung to the lymph nodes or other organs. TNM staging system is used to in the stage of lung cancers. This paper summarizes the 8th editio...
Molecular Imaging in Sarcoidosis and Amyloidosis
Sarcoidosis and amyloidosis can affect many organs, including the heart. The diagnosis of cardiac sarcoidosis and amyloidosis is very important because the prognosis of the patient depends on cardiac involvement and earl...
Imaging Probes Used in Multiple Imaging System (Dual Modality Probes)
Nowadays, with the increasing interest in personalized medicine and translational research, the need to develop disease-specific nanoprobes has arisen, leading to the development of systems that simultaneously perform mu...